Background:Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention(PCI)remain a challenge.A bioadaptor is a novel implant that addresses this issue by restoring the h...Background:Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention(PCI)remain a challenge.A bioadaptor is a novel implant that addresses this issue by restoring the haemodynamic modulation of the artery,allowing cyclic pulsatility,vasomotion,and adaptative remodelling,by unlocking and providing dynamic support to the artery.We aimed to assess outcomes with the device versus a contemporary drug-eluting stent(DES)in a representative PCI population.展开更多
文摘Background:Persistent non-plateauing adverse event rates in patients who underwent percutaneous coronary intervention(PCI)remain a challenge.A bioadaptor is a novel implant that addresses this issue by restoring the haemodynamic modulation of the artery,allowing cyclic pulsatility,vasomotion,and adaptative remodelling,by unlocking and providing dynamic support to the artery.We aimed to assess outcomes with the device versus a contemporary drug-eluting stent(DES)in a representative PCI population.
